Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Fexaramine, a non-absorbable FXR agonist that remains in the intestine, has shown potential in reducing diet-induced obesity and improving insulin sensitivity (Fang et al., 2015)
Survodutide Phase 2 Results The Phase 2 obesity trial for Survodutide enrolled 387 participants over 46 weeks with multiple dose levels tested
Mechanism of Action Pal-GHK exerts its activity by: Stimulating the synthesis of the extracellular matrix (ECM): This includes collagen, glycosaminoglycans, and other components essential for skin structure [1]
Many studies have shown that NAC can be an effective treatment for conditions like arthritis, inflammatory bowel disease, and even cancer